Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); and appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting.
2026 · 3rd Quarter (July 1 - Sep 30)
CARIS LIFE SCIENCES, INC.
Filed by CARIS LIFE SCIENCES, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $160,000.00
- Registrant
- CARIS LIFE SCIENCES, INC.
- Filing UUID
- fccdd0c7-3177-4377-99ef-b48f59a60dcc
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags; Medicare payment for Software as a Medical Service (SaMS)
Literal federal measure citations: S 2355
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.